PTC THERAPEUTICS, INC. (PTCT)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, PTC THERAPEUTICS, INC. reported revenue of $1.73B, up 114.5% from the prior year. The company was profitable, with a net margin of 39.4%. It held $2.90B in total assets against $3.10B in total liabilities.
Key ratios (FY2025)
50.1%
Operating margin
39.4%
Net margin
+114.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $806.78M | $937.82M | $698.80M | $538.59M | $380.77M | $306.98M | $264.73M | — | — |
| Cost of Revenue | — | — | — | — | — | — | $12.13M | $12.67M | $4.58M | — |
| Operating Income | $866.93M | -$302.57M | -$439.50M | -$447.41M | -$374.44M | -$431.77M | -$241.16M | -$115.69M | -$64.29M | -$132.06M |
| Net Income | $682.64M | -$363.30M | -$626.60M | -$559.02M | -$523.90M | -$438.16M | -$251.58M | -$128.08M | -$79.00M | -$142.11M |
| EPS (Diluted) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | — |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $391.65M | $269.35M |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768.50M | $235.22M | $149.76M |
| Shareholders' Equity | -$205.31M | -$1.10B | -$818.55M | -$347.09M | $1.44M | $481.98M | $594.33M | $350.73M | $156.44M | $119.58M |
| Cash & Equivalents | $984.65M | $779.71M | $594.00M | $279.83M | $189.72M | $208.81M | $288.03M | $169.50M | $111.79M | $58.32M |
| Operating Cash Flow | $711.20M | -$107.69M | -$158.42M | -$356.65M | -$251.33M | -$194.07M | -$98.64M | -$27.64M | -$10.06M | -$103.57M |
| Capital Expenditures | $8.86M | $6.50M | $28.44M | $32.02M | $28.21M | $17.84M | $13.76M | $7.10M | $3.10M | $1.78M |
| Shares Outstanding | 81.47M | 77.70M | 75.71M | 73.10M | 70.83M | 69.72M | 61.94M | 50.61M | 41.61M | 34.17M |